Fusen Pharmaceutical (1652.HK) Earnings Analysis
Fusen Pharmaceutical (1652.HK) has no confirmed upcoming earnings date. Trailing P/E -61.02.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1652.HK next report earnings?
No confirmed upcoming earnings date is currently scheduled for 1652.HK. This page updates as the calendar is published.
1652.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-06-30 | -0.03424 HKD | n/a | n/a | n/a |
| 2025-03-31 | -0.21849 HKD | n/a | n/a | n/a |
| 2024-08-29 | -0.05356 HKD | n/a | n/a | n/a |
1652.HK valuation and analyst view
| Trailing P/E | -61.02 |
|---|---|
| Trailing EPS | -0.0146 HKD |
| Price / book | 2.21 |
| Dividend yield | 0.00% |
| Market cap | 0.83B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Fusen Pharmaceutical (1652.HK)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 1652.HK. This page updates as the calendar is published.
Did 1652.HK beat earnings last quarter?
Consensus estimate data was not available for 1652.HK's 2025-06-30 report.
What is 1652.HK's current P/E ratio and EPS?
1652.HK trades at a trailing P/E of -61.02 on trailing EPS of -0.014595052864150936 HKD.
What do analysts rate 1652.HK?
1652.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.